Literature DB >> 28317873

A new method to evaluate the dose-effect relationship of a TCM formula Gegen Qinlian Decoction: "Focus" mode of integrated biomarkers.

Zhi-Qiang Huang1,2,3,4, Xue-Mei Fan2, Yi-Ming Wang2, Qiong-Lin Liang2, Xiao-Lin Tong5, Yu Bai6, Ying-Meng Li6, Guo-An Luo2,7, Chao Chen1,3,4.   

Abstract

It is difficult to accurately evaluate the efficacy of traditional Chinese medicine (TCM), which leads to the uncertainty and complexity of dose-effect analysis. In this study we established the "Focus" mode of biomarkers to characterize the dose-effect relationship of Gegen Qinlian Decoction (GQD), a TCM formula for treating type 2 diabetes mellitus (2-DM). A rat model of 2-DM was established through high fat diet feeding combined with low-dose STZ injection. Rats with 2-DM were administered high, middle or low doses (6.785, 4.071, 1.357 mg·kg-1·d-1, respectively) of GQD extract for 60 d. Metformin (300 mg·kg-1·d-1) was taken as the positive control. Blood samples were collected to assess serum biochemical indexes and metabolic profiling. After "Focus" analysis, the biochemical index triglycerides (TG) and insulin sensitivity (ISI) were identified as focused integrated biomarkers (FIBs), while arachidonic acid and docosatetraenoic acid were the metabolic FIBs. Dose-effect relationship curves of GQD were built based on these types of FIBs. Furthermore, the two dose-effect relationship curves showed similar trends with the middle dosage displaying the greatest efficacy, suggesting that insulin function and arachidonic acid metabolism played important roles in 2-DM and the responses to GQD. The metabolic FIB docosatetraenoic should be further explored for understanding its involvement in the process of 2-DM occurrence and the treatment. This "Focus" mode provides a novel strategy to evaluate the dose-effect relationship of a TCM. The system and concepts established here may also be applicable for assessing the dose-effect relationships of Western medicines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28317873      PMCID: PMC5547551          DOI: 10.1038/aps.2016.165

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  26 in total

Review 1.  The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.

Authors:  Eva Lonn; Jackie Bosch; Koon K Teo; Prem Pais; Denis Xavier; Salim Yusuf
Journal:  Circulation       Date:  2010-11-16       Impact factor: 29.690

2.  Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men.

Authors:  Gloria Lena Vega; Carolyn E Barlow; Scott M Grundy; David Leonard; Laura F DeFina
Journal:  J Investig Med       Date:  2014-02       Impact factor: 2.895

3.  Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.

Authors:  Frank M Sacks; Michel P Hermans; Paola Fioretto; Paul Valensi; Timothy Davis; Edward Horton; Christoph Wanner; Khalid Al-Rubeaan; Ronnie Aronson; Isabella Barzon; Louise Bishop; Enzo Bonora; Pongamorn Bunnag; Lee-Ming Chuang; Chaicharn Deerochanawong; Ronald Goldenberg; Benjamin Harshfield; Cristina Hernández; Susan Herzlinger-Botein; Hiroshi Itoh; Weiping Jia; Yi-Der Jiang; Takashi Kadowaki; Nancy Laranjo; Lawrence Leiter; Takashi Miwa; Masato Odawara; Ken Ohashi; Atsushi Ohno; Changyu Pan; Jiemin Pan; Juan Pedro-Botet; Zeljko Reiner; Carlo Maria Rotella; Rafael Simo; Masami Tanaka; Eugenia Tedeschi-Reiner; David Twum-Barima; Giacomo Zoppini; Vincent J Carey
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

4.  Biomarkers for early diagnosis of type 2 diabetic nephropathy: a study based on an integrated biomarker system.

Authors:  Min Huang; Qionglin Liang; Ping Li; Jianfei Xia; Yong Wang; Ping Hu; Zhiting Jiang; Yongxin He; Liqiong Pang; Lida Han; Yiming Wang; Guoan Luo
Journal:  Mol Biosyst       Date:  2013-05-30

5.  A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia.

Authors:  W J M van der Kemp; D W J Klomp; R S Kahn; P R Luijten; H E Hulshoff Pol
Journal:  Schizophr Res       Date:  2012-09-13       Impact factor: 4.939

Review 6.  Application of 'omics technologies to biomarker discovery in inflammatory lung diseases.

Authors:  Craig E Wheelock; Victoria M Goss; David Balgoma; Ben Nicholas; Joost Brandsma; Paul J Skipp; Stuart Snowden; Dominic Burg; Arnaldo D'Amico; Ildiko Horvath; Amphun Chaiboonchoe; Hassan Ahmed; Stéphane Ballereau; Christos Rossios; Kian Fan Chung; Paolo Montuschi; Stephen J Fowler; Ian M Adcock; Anthony D Postle; Sven-Erik Dahlén; Anthony Rowe; Peter J Sterk; Charles Auffray; Ratko Djukanovic
Journal:  Eur Respir J       Date:  2013-02-08       Impact factor: 16.671

7.  Fatty acid composition in the postmortem amygdala of patients with schizophrenia, bipolar disorder, and major depressive disorder.

Authors:  Kei Hamazaki; Tomohito Hamazaki; Hidekuni Inadera
Journal:  J Psychiatr Res       Date:  2012-05-08       Impact factor: 4.791

8.  Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes.

Authors:  Qibin Zhang; Thomas L Fillmore; Athena A Schepmoes; Therese R W Clauss; Marina A Gritsenko; Patricia W Mueller; Marian Rewers; Mark A Atkinson; Richard D Smith; Thomas O Metz
Journal:  J Exp Med       Date:  2012-12-31       Impact factor: 14.307

9.  Insulin resistance, type 1 and type 2 diabetes, and related complications: current status and future perspective.

Authors:  Joseph Fomusi Ndisang; Sharad Rastogi; Alfredo Vannacci
Journal:  J Diabetes Res       Date:  2014-03-18       Impact factor: 4.011

10.  Role of insulin resistance in the pathogenesis and development of type 2 diabetes in WBN/Kob-Lepr(fa) rats.

Authors:  Akira Okuno; Noriyuki Kaji; Atsushi Takahashi; Dai Nagakubo; Kanako Ohno-Ichiki; Mitsuyuki Shirai; Fumitoshi Asai
Journal:  J Vet Med Sci       Date:  2013-07-26       Impact factor: 1.267

View more
  6 in total

1.  Gegen Qinlian Decoction Coordinately Regulates PPARγ and PPARα to Improve Glucose and Lipid Homeostasis in Diabetic Rats and Insulin Resistance 3T3-L1 Adipocytes.

Authors:  Jun Tu; Shuilan Zhu; Bingtao Li; Guoliang Xu; Xinxin Luo; Li Jiang; Xiaojun Yan; Ruiping Zhang; Chen Chen
Journal:  Front Pharmacol       Date:  2020-06-11       Impact factor: 5.810

2.  Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials.

Authors:  Rongrong Zhou; Yujiao Zheng; Xuedong An; Fengmei Lian; Xiaolin Tong
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

3.  Metformin and Gegen Qinlian Decoction boost islet α-cell proliferation of the STZ induced diabetic rats.

Authors:  Li Xu; Shreyas Jois; Hongliang Cui
Journal:  BMC Complement Med Ther       Date:  2022-07-20

4.  Xiongshao Zhitong Recipe Attenuates Nitroglycerin-Induced Migraine-Like Behaviors via the Inhibition of Inflammation Mediated by Nitric Oxide Synthase.

Authors:  Song Yang; Cong Chen; Xiaoyao Liu; Qianjun Kang; Quantao Ma; Pin Li; Yujie Hu; Jialin Li; Jian Gao; Ting Wang; Weiling Wang
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

5.  The effect of Chinese herbal formulas combined with metformin on modulating the gut microbiota in the amelioration of type 2 diabetes mellitus: A systematic review and meta-analysis.

Authors:  Yunxi Xu; Shuyu Zheng; Shui Jiang; Junyu Chen; Xiaofang Zhu; Ya Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

Review 6.  A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine.

Authors:  Haiyu Xu; Yanqiong Zhang; Ping Wang; Junhong Zhang; Hong Chen; Luoqi Zhang; Xia Du; Chunhui Zhao; Dan Wu; Feng Liu; Hongjun Yang; Changxiao Liu
Journal:  Acta Pharm Sin B       Date:  2021-03-20       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.